Wells Fargo analyst Tim Evans started Danaher with a Market Perform rating and $90 price target.

Unusual total active option classes on open include: Steel Dynamics (STLD), Gildan Activewear (GIL), Danaher (DHR), Altimeter Growth (GRAB), Childrens Place (PLCE), ASML (ASML), US Bancorp (USB), iShares Barclays 7 to 10 Year Treasury Bond Fund (IEF), AMC Entertainment (AMC), and Abbott (ABT).

HSBC analyst Rajesh Kumar upgraded Danaher to Buy from Hold with a price target of $280, up from $250. HSBC's supply chain analysis suggests the de-stocking effects as well as order books might be on a recovery path for the life sciences tools sector, the analyst tells investors in a research note. The firm also believes the "geopolitical divide" of biotech funding around the U.S. Biosecure Act might result in a better pricing environment for outsourcers, potentially supporting incremental margins and multiples. It upgrades Danaher as a "quality proxy for the Biotech funding recovery."